Published: Dec, 2016
The global dilated cardiomyopathy therapeutics market is led by Novartis International AG, Merck & Co., Inc., and AstraZeneca plc. These three players accounted for over 80% of the market in 2013. Thus, the market is highly consolidated. Some of the other players in the market are Pfizer, Inc., Sanofi Aventis, Valeant Pharmaceuticals, Inc., and GlaxoSmithKline plc. Factors such as side effects of drugs, loss of patent exclusivity, and effective mechanism of action of these drugs against dilated cardiomyopathy symptoms play an important role in defining the market share of top players, states a new report by Transparency Market Research (TMR).
According to the report, the global dilated cardiomyopathy therapeutics market is expected to be worth US$328.6 mn by 2020. On the basis of drug class, the angiotensin II receptor blockers segment is expected to lead and be worth US$109.8 mn by 2020. The aldosterone antagonists segment however, will expand at a high CAGR of 18.4% from 2014 to 2020. By geography, North America will continue to lead in the market and is expected to be worth US$95.3 mn by 2020. The region is expected to lead in the dilated cardiomyopathy therapeutics market owing to a rise in the number of deaths due to heart attacks. An approximate of 5mn people are dying of heart failure in the U.S. alone. Of these, 550,000 patients are newly diagnosed. According to the U.S. Centers for Disease Control and Prevention, the total cost of cardiovascular disease incurred by the U.S. government was about US$444 bn in 2010. This expenditure is expected to grow exponentially. Thus, the market will be led by North America.
Growing Incidences of Heart Failures to Drive Global Dilated Cardiomyopathy Therapeutics Market
Heart diseases are a leading cause of death among both men and women worldwide. As dilated cardiomyopathy is one of the leading causes of heart failure, the mode of treatment for both of these conditions is similar. Around 6.7 mn deaths occurred due to stroke and around 7.4 mn deaths occurred due to coronary heart diseases in 2012, as per the World Health Organization. Growing incidences of congestive heart failure worldwide is resulting in an increased demand for effective medications for the treatment of the condition. This is enhancing the growth prospects of the dilated cardiomyopathy market.
Side Effects Associated with Use of Dilated Cardiomyopathy Therapeutics to Hinder Market
“Side effects associated with DCM therapeutics such as aldosterone antagonists and beta blockers, which are used to treat dilated cardiomyopathy is expected to hinder the acceptance of these drugs and thus, the market,” says a TMR analyst. These drugs negatively impact the functioning of kidneys and livers eventually. Aldosterone antagonists (spironolactone) has resulted in side effects such as seizures, electrolyte imbalance, convulsions, stomach bleeding, and weak pulse. Thus, patients are recommended to stop using these medications. Aldosterone antagonists in combination with angiotensin converting enzymes (ACE) inhibitors are lethal. They cause high potassium levels and poor kidney functionality.
It is expected that after receiving approval from regulatory bodies, gene therapy and stem cell therapy will be considered as the preferred treatment approaches against dilated cardiomyopathy. These two experimental approaches have shown promising results in DCM patients, but they are still at their investigational stages and not yet easily available. On the other hand, if drugs are specifically approved for dilated cardiomyopathy, it would create huge growth opportunities for the market players.
This information is based on the findings of a report published by Transparency Market Research titled “Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020.”
The global dilated cardiomyopathy therapeutics market is segmented as follows:
Dilated Cardiomyopathy Therapeutics Market, by Drug Class
- Aldosterone antagonists
- Angiotensin-converting enzyme (ACE) inhibitors
- Angiotensin II receptor blockers (ARBs)
Dilated Cardiomyopathy Therapeutics Market, by Pipeline Drugs
Dilated Cardiomyopathy Therapeutics Market, by Geography
- North America
- Asia Pacific
- Rest of the World (RoW)
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453